Loading
A phase 1/2 trial of Ribociclib, Fulvestrant in small-cell lung cancer, run by Novartis Pharmaceuticals, now recruiting.
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06726148 by Novartis Pharmaceuticals, with 280 participants planned, started 2025-04-03 and due to reach its primary completion in 2028-09-25. Interventions recorded: ECI830, ribociclib, fulvestrant. Conditions listed: Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ribociclib, CDK4/6 inhibitors, Novartis.
Shares Ribociclib, CDK4/6 inhibitors, Novartis.
Shares Ribociclib, Fulvestrant, CDK4/6 inhibitors.
Shares Fulvestrant, Novartis.
Shares Ribociclib, Fulvestrant, CDK4/6 inhibitors.
Shares Fulvestrant, CDK4/6 inhibitors.
Shares Fulvestrant, CDK4/6 inhibitors.
Shares Ribociclib, Novartis, Small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/